MGO One Seven’s Dianthus Therapeutics DNTH Stock Holding History

MGO One Seven’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19	Closed	-$1K	–	700
2018 Q4	$1K	Buy	+19	New	+$2.59K	﹤0.01%	1667

Other funds holding DNTH

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

MGO One Seven's DNTH Position: Q1 2019 in Review

MGO One Seven sold out of Dianthus Therapeutics (DNTH) in Q1 2019, closing a stake of 19 shares — an estimated $1K sold.

MGO One Seven first reported a position in DNTH in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 63 funds tracked by Wall St. Rank hold DNTH as of Q1 2019.

MGO One Seven reported no remaining Dianthus Therapeutics position as of Q1 2019 after selling out during the quarter.
MGO One Seven sold 19 Dianthus Therapeutics shares in Q1 2019, an estimated $1K.
MGO One Seven first reported a position in Dianthus Therapeutics in Q4 2018 and held it in 1 quarter.
MGO One Seven's Dianthus Therapeutics position peaked at $1K in Q4 2018.
63 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2019.

Based on MGO One Seven's 13F filing for Q1 2019, filed 9 Apr 2019.